ACIXF (Acarix AB) Total Equity: $3.97 Mil (As of Mar. 2026)


ACIXF Acarix AB ACIXF
47 GF Score
Price $0.03
GF Value $0.02
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Acarix AB Total Equity?

Acarix AB ACIXF 47 Total Equity is $3.97 Mil as of Mar. 2026. GuruFocus rates ACIXF with a GF Score™ of 47/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Acarix AB's total equity for the quarter that ended in Mar. 2026 was $3.97 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Acarix AB Total Equity Historical Data

* Premium members only.

The historical data trend for Acarix AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acarix AB Total Equity Chart

Acarix AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.06 4.99 5.06 6.89 4.11

Acarix AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.91 5.00 4.11 4.11 3.97
ACIXF
47GF Score
Acarix AB ACIXF
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acarix AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Acarix AB's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=5.2-1.093
=4.11

Acarix AB's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=4.669-0.703
=3.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $3.97 Mil mean?
Acarix AB (ACIXF) has a Total Equity of $3.97 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Acarix AB and its competitors.
Is Acarix AB's Total Equity too high?
Acarix AB's current Total Equity is $3.97 Mil. Overall, Acarix AB has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's Total Equity compare to ABT and SYK?
Acarix AB's Total Equity of $3.97 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Acarix AB and its competitors. Acarix AB's current Total Equity is $3.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (ACIXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 45% above its estimated fair value. The current Total Equity is $3.97 Mil. Acarix AB's overall GF Score™ is 47/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Acarix AB (ACIXF), the current Total Equity is $3.97 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Acarix AB (ACIXF) Overvalued in 2026?

Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued. The current stock price of $0.03 is trading 45% above its estimated GF Value™ of $0.02. GuruFocus considers Acarix AB to be Significantly Overvalued.

Key valuation signals for ACIXF:

  • Total Equity: $3.97 Mil
  • GF Value™: $0.02 vs. price of $0.03 (45% above fair value)
  • GF Score™: 47/100 with 1 warning sign

No single metric tells the full story. See the ACIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Acarix AB Business Description

Other Exchanges ACARIX:Sweden
Address Hyllie Boulevard 34, Regus Malmo, Malmo, SWE, 215 32
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
47GF Score

Get the complete analysis for ACIXF

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.03
Price
$0.02
GF Value